KCI Biotech (Suzhou) Inc. and its wholly owned subsidiary Jiangsu KMQ Biotech Inc. are dedicated to providing comprehensive preclinical drug discovery and development services to global pharmaceutical companies and research institutions. Our mission is to support the advancement of innovative therapies by offering an integrated and efficient drug research and development evaluation system.
We operate two state-of-the-art laboratory animal facilities in Suzhou and Nantong, each certified by the International Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). Spanning over 18,000 square meters, these facilities are equipped to support a wide range of preclinical research needs.
Our diverse and fully equipped laboratory animal platforms include species such as mice, hamsters, guinea pigs, rabbits, cats, dogs, pigs, ferrets, and non-human primates. With access to over 400 animal models for both oncological and non-oncological diseases, we provide a comprehensive suite of research services. These include:
● In Vivo pharmacology Experimental Platforms
● ABSL-2/BSL-2 Microbiology Experimental Platforms
● Pathology Services Platforms
● Cell and Molecular Biology Research Platforms
● Pharmacokinetics Studies Platforms
● Medical Imaging Platforms
At KCI Biotech, we are committed to advancing scientific discovery with the highest standards of research excellence, precision, and safety.
